Skip to content

Guardant Health GH Investing Cash Flow

Investing Cash Flow at other companies

Myriad Genetics logo
Myriad GeneticsMYGN
-$6.5M+21.7%
NeoGenomics logo
NeoGenomicsNEO
-$8.32M+10.7%
Illumina logo
IlluminaILMN
-$121M-147%
Veracyte logo
VeracyteVCYT
-$127.96M-147%
Biodesix, Inc. logo
Biodesix, Inc.BDSX
-$144K-5.1%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
$9.14M-64.2%

Other financials

Income statement

See full
Revenue$301.7M+48.3%
Gross profit$196.7M+52.8%
Operating income-$121.4M-9.3%
Net income-$112.1M-17.8%
EPS (diluted)-$0.85-10.4%

Balance sheet

See full
Cash & equivalents$1.1B+37.0%
Total debt$1.7B+30.5%
Total equity-$181.1M+27.8%
Total assets$1.9B+42.5%

Cash flow

See full
Operating cash flow-$65.6M-4.7%
CapEx$5.6M+25.1%
Free cash flow-$71.2M-6.0%

Valuation

See full
Market cap$19.04B+255%
Enterprise value$19.65B+229%
P/S17.6×+11.2×

Profitability

See full
Gross margin64.9%+3.6pp
Operating margin-41.4%-9.4pp
Net margin-40.1%-8.1pp
FCF margin-22%-6.7pp

Returns & leverage

See full
Return on equity-438.1%-1,655pp
Debt / equity
Current ratio4.7×+0.6×

Where this comes from

Reported directly by Guardant Health in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Guardant Health’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Guardant Health's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Guardant Health's investing cash flow?
Guardant Health (GH) reported investing cash flow of $699.42M in Q1 2026.
How has Guardant Health's investing cash flow changed year-over-year?
Guardant Health's investing cash flow increased by 130.9% year-over-year, from $302.86M to $699.42M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.